Search Results
Your search for ,twO matches 12057 pages
Showing 1501 - 1550Long-Term Results of European Pediatric Soft-Tissue Sarcoma Study in Nonmetastatic Rhabdomyosarcoma
In an analysis reported in the Journal of Clinical Oncology, Gianni Bisogno, MD, PhD, and colleagues detailed 5-year outcomes among children and adolescents with nonmetastatic rhabdomyosarcoma in the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Study Details The RMS2005 study...
Pilot Program Shows Diversity-Focused Clinical Trial Tools Are Useful at Cancer Research Sites
Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published recently in JCO Oncology Practice.1,2 The studies examine the results from a collaborative...
Highlights of the 2022 Annual Conference of the International Society of Geriatric Oncology
The 2022 Annual Conference of the International Society of Geriatric Oncology (SIOG) was held in Geneva, Switzerland, on October 28–30, 2022. The meeting was held in conjunction with the SIOG 2022 Public Policy Meeting: Global Policy to Action on Cancer in the Aging Population at UN Headquarters...
Sacituzumab Govitecan-hziy in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On February 3, 2023, sacituzumab govitecan-hziy was approved for unresectable locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization–negative) breast cancer who have received endocrine-based therapy and at...
Nicotinamide for Chemoprevention of Skin Cancer in Solid Organ Transplant Recipients
In an Australian phase III trial (ONTRANS) reported in The New England Journal of Medicine, Allen et al found that 1 year of treatment with nicotinamide (vitamin B3) vs placebo did not reduce the risk of keratinocyte cancers or actinic keratoses in immunosuppressed solid organ transplant...
Blood Test May Identify Patients With AML at Greater Risk of Relapse After Bone Marrow Transplant
Researchers have found that screening for residual disease prior to a bone marrow transplant may help physicians identify which adult patients in remission from acute myeloid leukemia (AML) are at risk of relapsing after the procedure, according to a novel study published by Dillon et al in JAMA....
Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On January 27, 2023, elacestrant was approved by the U.S. Food and Drug Administration (FDA) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine ...
Phase III Trials Confirm Benefit of First-Line Anti–PD-1 Inhibition Plus Chemotherapy in Gastric Cancer
Two phase III trials evaluating the addition of drugs targeting PD-1 to chemotherapy—RATIONALE 305 and CheckMate 649—confirmed the benefit of this approach as first-line therapy for advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma, in findings presented at the 2023 ASCO GI...
Working Together to Close the Global Care Gap
The COVID-19 pandemic has underscored that public health is the product of one global, integrated ecosystem. Although it is tempting to focus on specific aspects of local health-care systems, or the political or physical environment, health and health care in other countries also impacts the United ...
TRITON3 Trial: Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer whose tumors harbored BRCA or ATM alterations. These results of the phase III TRITON3 study ...
Nivolumab Followed by Nivolumab/Ipilimumab Boosting in Nonresponders Among Previously Treated Patients With Advanced Urothelial Carcinoma
In a German-Austrian phase II study (TITAN-TCC) reported in The Lancet Oncology, Grimm et al found that a strategy of nivolumab monotherapy followed by immunotherapeutic boosting including high-dose ipilimumab in nivolumab nonresponders showed activity in patients with unresectable or metastatic...
Fewer Cases of Melanoma and Extracutaneous Malignancies Detected Among Patients With Atopic Diseases
Researchers have found that patients with a history of atopic diseases may be less likely to develop melanoma than patients with a history of nonatopic diseases, according to a new study published by Komulainen et al in Melanoma Research. The findings also revealed that patients with atopic...
Early Intervention for Steroid-Refractory Chronic Graft-vs-Host Disease
This is Part 2 of Clinical Considerations in Chronic Graft-vs-Host Disease, a two-part video roundtable series. In this video, Dr. Yi-Bin Chen and Dr. Mitchell E. Horwitz discuss the case of a 65-year-old woman with inversion 16 acute myeloid leukemia who is in second complete remission. She...
Early Detection of Chronic Graft-vs-Host Disease
This is Part 1 of Clinical Considerations in Chronic Graft-vs-Host Disease, a two-part video roundtable series. In this video, Dr. Yi-Bin Chen and Dr. Mitchell E. Horwitz discuss the case of a 55-year-old man with FLT3-ITD–mutated acute myeloid leukemia in first complete remission who received a...
Depression May Be Linked to Higher Levels of Inflammation, Poorer Outcomes in Patients With Lung Cancer
Patients with lung cancer who have moderate to severe depression may be two to three times more likely to have inflammation levels that predict poor survival rates, according to a new study published by Andersen et al in PLOS One. The findings may help explain why a substantial portion of patients...
Studies Focusing on Age- and Race-Related Disparities in Multiple Myeloma and Sickle Cell Disease
Research that addresses the compounding effects of age and race/ethnicity on access to quality health care and patient-centered outcomes such as physical function, frailty, and survival continues to be an emerging area of inquiry in hematology. Accordingly, novel research employing qualitative and...
Dinutuximab Beta and Interleukin-2 After Haploidentical Stem Cell Transplantation in Patients With Relapsed Neuroblastoma
In a phase I/II trial reported in the Journal of Clinical Oncology, Flaadt et al found that treatment with the anti-GD2 antibody dinutuximab beta plus low-dose interleukin-2 (IL-2) following haploidentical stem cell transplantation (haplo-SCT) is feasible in patients with relapsed high-risk...
Neoadjuvant Plus Adjuvant vs Adjuvant Pembrolizumab in Advanced Melanoma
In the phase II SWOG Cancer Research Network S1801 trial reported in The New England Journal of Medicine, Sapna P. Patel, MD, and colleagues found that neoadjuvant plus adjuvant pembrolizumab significantly improved event-free survival vs adjuvant pembrolizumab alone in patients with stage IIIB to...
Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma: 5-Year Results of the ZUMA-1 Trial
As reported in the journal Blood by Sattva S. Neelapu, MD, and colleagues, 5-year outcomes from the the phase II ZUMA-1 trial showed that axicabtagene ciloleucel was associated with maintained response in one-third of patients with refractory large B-cell lymphoma. The estimated 5-year overall...
FDA Expands Early Breast Cancer Indication for Abemaciclib Plus Endocrine Therapy
On March 3, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio) plus endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer at high risk of...
First-Line Pembrolizumab in Older Patients With dMMR Metastatic Colorectal Cancer
In a retrospective cohort study reported in JAMA Network Open, Saberzadeh-Ardestani et al found that first-line pembrolizumab was associated with clinically significant prolongation of survival outcomes in mostly older patients with mismatch repair–deficient (dMMR) metastatic colorectal cancer....
Access to Paid Sick Leave May Result in More Cancer Screenings
More individuals may undergo cancer screenings when employers are mandated to provide paid sick leave, according to a new study published by Callison et al in The New England Journal of Medicine. Researchers found that breast cancer screening rates increased up to 4% and colorectal cancer...
Can Long Noncoding RNA Expression Help Predict Outcomes in Pediatric Patients With AML?
In a study reported in the Journal of Clinical Oncology, Farrar et al developed a long noncoding RNA (lncRNA) transcription scoring system that distinguished survival outcomes in pediatric patients with acute myeloid leukemia (AML). As stated by the investigators, “Risk classification in pediatric...
How Patient Navigation Programs Are Helping Drive Equitable Care for Patients With Cancer and Improve Outcomes
Although patient navigation is increasingly recognized as an important component in the delivery of patient-centered cancer care, the service is not universally available across all cancer programs in the United States, often because of the concerns of extra cost without tangible financial...
Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients With Non–Muscle-Invasive Bladder Cancer Amid BCG Shortage
Researchers have found that a safe, inexpensive chemotherapy combination may be better tolerated and more effective at preventing high-grade recurrence in patients with non–muscle-invasive bladder cancer than the standard-of-care bacillus Calmette-Guérin (BCG), according to a novel study published...
Prediction Models for Kidney Failure in Long-Term Survivors of Childhood Cancer
In a study reported in the Journal of Clinical Oncology, Wu et al developed models for predicting kidney failure among 5-year survivors of childhood cancer. Study Details In the study, predictive models were developed using data from 25,483 survivors from the Childhood Cancer Survivor Study (CCSS)...
Survival in Patients With Brain Metastases: Limited or Stable Extracranial Disease
In a systematic review and meta-analysis reported in JAMA Network Open, Li et al found that patients with intracranial metastatic disease in the context of limited or stable extracranial disease (IMD-SE) secondary to any primary cancer had improved overall survival vs those with intracranial...
Hospital Surgical Volume May Impact Survival in Patients With Pancreatic Cancer Whose Minimally Invasive Surgery Is Converted to an Open Procedure
Patients with pancreatic ductal adenocarcinoma whose pancreatoduodenectomy is converted to an open (CTO) procedure from a minimally invasive procedure as a result of complications may fare better at institutions that perform more minimally invasive pancreatic cancer surgeries annually, according to ...
Combination Abatacept, Ruxolitinib, and/or Mechanical Ventilation May Decrease Mortality in Patients With Immune Checkpoint Inhibitor–Associated Cardiotoxicity
Although immune checkpoint inhibitors have substantially improved clinical outcomes in many cancer types, they have also been found to induce immune-related adverse events, including myocarditis, in about 1% of patients receiving the agents, which can lead to a mortality rate of up to 50%. Current...
Darolutamide Plus ADT and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer: Outcomes by Disease Volume and Risk Status in the ARASENS Trial
In an analysis from the phase III ARASENS trial reported in the Journal of Clinical Oncology, Maha Hussain, MD, FACP, FASCO, and colleagues found that the addition of darolutamide to androgen-deprivation therapy (ADT) and docetaxel significantly improved overall survival in subgroups of patients...
2023 ASCO Genitourinary Cancers Symposium: Focus on RCC
On this episode, we’re sharing news from our coverage of data presented at the 2023 ASCO Genitourinary Cancers Symposium, which took place recently in San Francisco. We’ll hear from two researchers about their findings in renal cell carcinoma (RCC).
ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreaK100, Other Trials
ASCO has updated its living guidelines for therapy for stage IV non–small cell lung cancer (NSCLC) with and without driver alterations based on newly available evidence in the field.1,2 “Living guidelines are becoming more important as the field of oncology expands and developments occur more...
ASCO Endorses CAP Guideline to Better Define Who Benefits From Immune Checkpoint Inhibitor Therapy
ASCO has endorsed a new guideline from the College of American Pathologists (CAP) on the use of mismatch repair (MMR) and microsatellite instability (MSI) testing, which could help oncologists more accurately identify patients who may be suitable candidates for immune checkpoint inhibitor ...
INTRIGUE Study: Circulating Tumor DNA Analysis May Predict Optimal Treatment of Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help to predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented during the ASCO Plenary Series: January 2023 Session.1 Exploratory analysis of the phase...
Expert Point of View: Pretesh R. Patel, MD
Session co-moderator, Pretesh R. Patel, MD, Associate Professor of Radiation Oncology at Winship Cancer Institute of Emory University, shared his thoughts on the Neo-AEGIS1 findings with The ASCO Post. “I think we continue to have equipoise about chemoradiation and perioperative chemotherapy in...
Neo-AEGIS Trial Finds Two Approaches Comparable in Treating Advanced Esophageal Cancer
A randomized trial that sought to determine the optimal approach to treating locally advanced esophageal or gastroesophageal junction cancer has ended in “equipoise,” according to the investigators of the Neo-AEGIS trial. In a study reported at the 2023 ASCO GI Cancers Symposium, perioperative...
Expert Point of View: Laura Goff, MD, MSCI
Invited discussant Laura Goff, MD, MSCI, Associate Professor of Medicine and Executive Medical Director for the Cancer Patient Care Center at Vanderbilt-Ingram Cancer Center, Nashville, said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic...
First-Line NALIRIFOX Improves Survival in Metastatic Pancreatic Cancer
In the phase III NAPOLI-3 trial in previously untreated patients with metastatic pancreatic cancer, the NALIRIFOX regimen significantly improved overall survival and progression-free survival over nab-paclitaxel plus gemcitabine.1 NALIRIFOX, which contains liposomal irinotecan, fluorouracil,...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
Understanding the Health Disparities That Sexual and Gender Minorities Face in Oncology Care
In its programming for the 2022 ASCO Annual Meeting, ASCO included a special Education Session on “Gender-Based and Sexual Orientation Inequities: Promoting Inclusion, Visibility, and Data Accuracy in Oncology.” The session offered a comprehensive discussion on the challenges that sexual and gender ...
Addition of Bevacizumab to Trifluridine/Tipiracil: New Standard of Care in Refractory Colorectal Cancer
In the open-label phase III SUNLIGHT trial, the addition of bevacizumab to trifluridine/tipiracil, also known as TAS-102, significantly improved overall survival in patients with metastatic treatment-refractory colorectal cancer,1 according to Josep Tabernero, MD, Head of the Department of Medical...
KarMMa-3: Idecabtagene Vicleucel vs Standard Regimens in Patients With Relapsed or Refractory Multiple Myeloma
As reported in The New England Journal of Medicine by Rodriguez‑Otero et al, an interim analysis of the phase III KarMMa-3 trial showed superior progression-free survival with the B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel) vs...
Neighborhood Social Vulnerability and Its Influence on the Availability of Clinical Trials in Multiple Myeloma
Clinical trials set the treatment standards for cancer care. However, for select populations, such as those who are older, Black, or facing socioeconomic challenges, access to clinical trials and health care generally remains limited. Barriers to clinical trial participation are numerous and...
First-Line Tyrosine Kinase Inhibitor Therapy for Advanced Clear Cell Renal Cell Carcinoma: Temporary Treatment Cessation vs Continuation
As reported in The Lancet Oncology by Brown et al, the phase II/III STAR trial showed that noninferiority in overall survival and quality-adjusted life-years (QALYs) could not be concluded for temporary treatment cessation vs continuous treatment with first-line tyrosine kinase inhibitor therapy in ...
Expert Point of View: Robert Rifkin, MD
Smoldering myeloma is an asymptomatic plasma cell disorder with a heterogeneous clinical behavior. Two trials presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition investigated early intervention for smoldering multiple myeloma, aiming for a “curative strategy”...
Triplet and Quadruplet Regimens in Smoldering Multiple Myeloma
Combination regimens beyond lenalidomide/dexamethasone were shown to significantly delay—and potentially prevent altogether—progression from smoldering disease to active multiple myeloma, according to researchers who reported findings from two studies at the 2022 American Society of Hematology...
Pediatric Patients With ALL Living Along the Texas-Mexico Border May Experience Lower Rates of Survival
Investigators have found that pediatric patients with acute lymphoblastic leukemia (ALL) who lived along the Texas-Mexico border were more likely to die within 5 years than those living in other areas of the state, according to a new study published by Castellanos et al in Cancer. Background...
Addition of Avelumab to Carboplatin/Paclitaxel in First-Line Treatment of Advanced or Recurrent Endometrial Cancer
As reported in The Lancet Oncology by Sandro Pignata, MD, and colleagues, the Italian phase II MITO END-3 trial showed no progression-free survival benefit with the addition of first-line avelumab to carboplatin/paclitaxel in patients with advanced or recurrent endometrial cancer. A trend toward...
Abstracts of Interest on Novel Therapies for Gastrointestinal Cancers
As in the years before the COVID-19 pandemic, the 2023 ASCO GI Cancers Symposium—its 20th such gathering—played to a full ballroom. It featured a stellar lineup of experts in the field as well as high-quality, impactful research in esophageal, gastric, hepatocellular, pancreatic, biliary tract, and ...
Nivolumab and Relatlimab in Patients With Advanced Melanoma Progressing on Anti–PD-1/PD-L1 Therapy
As reported in the Journal of Clinical Oncology by Paolo Antonio Ascierto, MD, and colleagues, the phase I/IIa RELATIVITY-020 trial part D has shown evidence of activity of the combination of nivolumab and relatlimab in patients with advanced melanoma progressing on anti–PD-1/PD-L1 therapy. Study...
